2 messages
BMY
BMY Q2 Beat: Cost Discipline & Strategic Shifts
Jul 31, 2025, 06:05 PM
Quarterly Post-Earnings Summary
Bristol Myers Squibb beat Q2 expectations with strong cost controls and strategic initiatives, but faces ongoing risks from one-off charges and legacy product declines.
BMY
BMY: Innovation Drives Margin Recovery Amid Headwinds
Jul 29, 2025, 12:09 PM
Earnings Outlook
Bristol Myers Squibb’s innovation-driven growth and cost discipline are offsetting legacy declines, supporting margin and EPS resilience despite ongoing regulatory and pricing risks.